Swedish probiotics player sales surge 16%

By Shane Starling

- Last updated on GMT

Related tags: Lactobacillus, Probiotic, Lactobacillus reuteri

BioGaia has been investing in clinical research in 2010
BioGaia has been investing in clinical research in 2010
Swedish probiotics supplier and product manufacturer BioGaia has seen sales increase 16 per cent in 2010 to €27.77m from €23.08m in 2009, with after-tax profit increasing 31 per cent year-on-year to €5.35m.

Q4 after-tax profit jumped 90 per cent to €1.46m.

“On the whole, we thus had a very strong development during 2010 and are building value by investing further in clinical research, product development and the BioGaia brand,"​ said BioGaia president Peter Rothschild.

The company highlight research advances in Q4. These included the publication of a study demonstrating Lactobacillus reuteri Protectis​ is effective in treatment of periodontitis, a common, chronic inflammatory disease that is characterised by gum tissue separation from the tooth – forming a periodontal pocket that can lead to bone and tooth loss.

Another study found Lactobacillus reuteri Protectis​ reduced regurgitation and improved stomach emptying in infants.

Partnerships

The company also signed two significant agreements in Q4, one in Greece for its Oral Rehydration Solution.

Its 50 per cent-owned company, TwoPac, which manufactures advanced ingredient delivery systems also established a new facility in Eslöv, Sweden.

Correction: This article has been amended to remove inadvertent references to another Swedish probiotics supplier.

Related news

Show more

Related products

show more

A Promising Product for Comprehensive Men's Health

A Promising Product for Comprehensive Men's Health

Chemical Resources (CHERESO) | 17-Jun-2019 | Clinical Study

Testosterone deficiency is increasingly recognized as a significant health problem in men. Testosterone deficiency can adversely affect sexual function,...

Fermented Soy for Natural Digestive Support

Fermented Soy for Natural Digestive Support

Lallemand Bio-Ingredients | 22-Apr-2019 | Technical / White Paper

Lallemand is running a new clinical trial for Gastro-AD® in spring 2019. Gastro-AD® is a clinically studied food supplement based on non-GMO soy fermented...

Related suppliers

1 comment

Teamwork

Posted by Jason Ryz,

Probi is an excellent company that I am glad is doing well in such a competitive market. Probi should consider merging with a US-based company because the market is rapidly increasing.

Report abuse

Follow us

Featured Events

View more

Products

View more

Webinars